The call highlighted significant advancements in clinical trials and a strong financial position, indicating optimism about the future potential of AXPAXLI. The challenges mentioned, such as adjustments in rescue criteria, were addressed strategically, reflecting confidence in the drug's profile.

Company Guidance -

Q3 2025

During the Ocular Therapeutix Second Quarter 2025 Earnings Conference Call, significant guidance was provided regarding the company's strategic plans and clinical trials progress. The focus was on the registrational program for AXPAXLI in wet AMD, highlighting the SOL-1 and SOL-R studies. The SOL-1 trial, with 344 patients randomized, aims for a superiority claim and has a Special Protocol Assessment (SPA) agreement with the FDA. The SOL-R trial is designed to demonstrate non-inferiority with a 90% power at a margin of minus 4.5 letters, comparing AXPAXLI dosed every 24 weeks to aflibercept dosed every 8 weeks. The call also detailed plans for a long-term open-label extension study for both SOL trials to gather real-world insights and long-term safety data. Financially, Ocular Therapeutix reported over $390 million in cash, providing a runway into 2028, following a $97 million capital raise through an ATM facility. The company plans to host an Investor Day on September 30, 2025, to further discuss its strategy and commercial opportunities, particularly in expanding into nonproliferative diabetic retinopathy and diabetic macular edema.

Strong Financial Position

Ocular Therapeutix ended the second quarter with over $390 million in cash and cash equivalents. The company raised approximately $97 million through an existing ATM facility, providing financial flexibility and expected runway into 2028.

Progress in AXPAXLI Trials

The SOL-1 and SOL-R trials are advancing with exceptional retention and trial conduct. SOL-1 is on track to provide top-line data in Q1 2026, and SOL-R is expected to have top-line data in the first half of 2027.

Potential Superiority Label for AXPAXLI

If approved, AXPAXLI could be the first product for wet AMD with a superiority claim, potentially allowing dosing every 6 to 12 months, significantly reducing treatment burden for patients.

Strategic Open-Label Extension Study

The company plans a long-term open-label extension study for both SOL-1 and SOL-R trials to generate real-world insights and long-term safety data, which could enhance commercial adoption.

Expansion into Diabetic Eye Disease

Ocular Therapeutix is preparing to expand AXPAXLI into nonproliferative diabetic retinopathy and diabetic macular edema, following positive FDA feedback.

Ocular Therapeutix (OCUL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OCUL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.38 / -	-0.22	―	―	―
Aug 05, 2025	2025 (Q2)	-0.36 / -0.39	-0.26	-50.00% (-0.13)	―
May 05, 2025	2025 (Q1)	-0.29 / -0.38	-0.49	22.45% (+0.11)	―	―
Mar 03, 2025	2024 (Q4)	-0.25 / -0.29	-0.35	17.14% (+0.06)	―
Nov 14, 2024	2024 (Q3)	-0.24 / -0.22	-0.006	-3566.67% (-0.21)	―
Aug 07, 2024	2024 (Q2)	-0.22 / -0.26	-0.26	0.00% (0.00)	―
May 07, 2024	2024 (Q1)	-0.19 / -0.49	-0.39	-25.64% (-0.10)	―	―
Mar 11, 2024	2023 (Q4)	-0.30 / -0.35	-0.2	-75.00% (-0.15)	―	―
Nov 07, 2023	2023 (Q3)	-0.29 / >-0.01	-0.31	98.06% (+0.30)	―
Aug 07, 2023	2023 (Q2)	-0.30 / -0.26	-0.25	-4.00% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OCUL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$12.35	$12.00	-2.83%
May 05, 2025	$8.80	$7.73	-12.16%
Mar 03, 2025	$7.14	$5.92	-17.09%
Nov 14, 2024	$10.60	$9.92	-6.42%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ocular Therapeutix Inc (OCUL) report earnings?

Ocular Therapeutix Inc (OCUL) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Ocular Therapeutix Inc (OCUL) earnings time?

Ocular Therapeutix Inc (OCUL) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OCUL EPS forecast?

OCUL EPS forecast for the fiscal quarter 2025 (Q3) is -0.38.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing